Search | Clinical Trials Finder

Conditions: Hemophilia B
Interventions: AAV5-hFIXco-Padua (AMT-061); Genetic
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Phoenix, Arizona • Sacramento, California • San Diego, California + 1 more

Conditions: Intracranial Hemorrhage
Interventions: Use of fixed-dosed 4F-PCC; Procedure
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years to 75 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Congenital Bleeding Disorder, Haemophilia B
Interventions: nonacog beta pegol; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Cincinnati, Ohio • Portland, Oregon • Richmond, Virginia

Conditions: Healthy
Interventions: Rivaroxaban, Tranexamic acid, Kcentra, a 4-factor PCC, Saline; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 158 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hemophilia a, Hemophilia B
Interventions: SerpinPC; Drug
Lead sponsor: ApcinteX Ltd; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Aurora, Colorado • Tampa, Florida • Indianapolis, Indiana + 7 more

Conditions: Hemophilia
Interventions: Coagulation Factor VIIa (Recombinant); Biological
Lead sponsor: Laboratoire français de Fractionnement et de Biotechnologies; Industry
Eligibility: 6 Months to 75 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hemophilia B, Hemophilia B, Moderately Severe or Severe
Interventions: BE-101; Drug
Lead sponsor: Be Biopharma; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Davis, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 2 more

Conditions: Hemophilia
Interventions: Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC); Drug · Biological
Lead sponsor: Sanofi; Industry
Eligibility: 1 Year to 11 Years · Male only
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Las Vegas, Nevada + 2 more

Conditions: Complex Cardiovascular Surgery With Cardiopulmonary Bypass
Interventions: BE1116, FFP; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 12 more

Conditions: Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke, Cerebrovascular Disease
Interventions: Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia, Hyperglycemia treatment, Do-not-resuscitate (DNR) or withdrawal of care, Referral to Intensive Care, Referral to Neurosurgery, Repeat brain imaging, Standard care; Other · Diagnostic Test
Lead sponsor: Region Skane; Other
Eligibility: 18 Years and older
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Anticoagulation, Anticoagulation Reversal
Interventions: four factor prothrombin complex concentrate; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Reversal of Anticoagulant Treatment
Interventions: Octaplex (human prothrombin complex concentrate), Fresh frozen plasma; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hemophilia B
Interventions: Non-Interventional; Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Aurora, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more

Conditions: Von Willebrand Disease, Type 3
Interventions: Von Willebrand Factor Concentrates, Von Willebrand Factor Concentrates and Factor VIII Concentrates, Factor VIII Concentrates, Recombinant Activated Factor VII, Activated Prothrombin Complex Concentrate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Sacramento, California • Minneapolis, Minnesota • St Louis, Missouri

Conditions: Intracranial Hemorrhage, Traumatic, Intracranial Hemorrhage, Spontaneous
Interventions: Four Factor Prothrombin Complex Concentrate, Fresh Frozen Plasma; Drug · Biological
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Factor VIII Deficiency, Congenital
Interventions: Emicizumab; Drug
Lead sponsor: Indiana Hemophilia &Thrombosis Center, Inc.; Other
Eligibility: 5 Years to 45 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hemophilia
Interventions: Fitusiran, BPA prophylaxis, Factor (FVIII or FIX) prophylaxis; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: activated recombinant human factor VII, factor IX, factor VIII; Drug · Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 5 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 14
States / cities: Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more

Conditions: Hemophilia B
Interventions: AAV5-hFIXco-Padua; Genetic
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 15
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 11 more

Conditions: Bleeding, Blood Loss, Surgical, Cardiovascular Surgical Procedures, Prothrombin Complex Concentrates, Fresh Frozen Plasma
Interventions: Prothrombin complex concentrate (Human), Fresh frozen plasma (FFP); Drug · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Anticoagulant-related Major Bleed
Interventions: Andexanet alfa, 4F-PCC; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 5,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Agoura Hills, California

Conditions: Hemophilia B, Allergic Reactions
Interventions: Not listed
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: Not listed
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 15
States / cities: Phoenix, Arizona • Orange, California • Atlanta, Georgia + 12 more

Conditions: Hemophilia B
Interventions: CSL222 (AAV5-hFIXco-Padua); Genetic
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 4
States / cities: San Diego, California • Ann Arbor, Michigan • Pittsburgh, Pennsylvania + 1 more

Conditions: Hemophilia B
Interventions: rIX-FP; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 4
States / cities: Chicago, Illinois • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more

Search by objective public record fields.

Dose Confirmation Trial of AAV5-hFIXco-Padua

Evaluation of 4-Factor PCC in DOAC-associated Intracranial Hemorrhage

Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B

A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants

The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures

BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)

International Care Bundle Evaluation in Cerebral Hemorrhage Research

Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC)

Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures

A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

FFP Versus PCC in Intracranial Hemorrhage

Hemlibra in Mild Hemophilia A

A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding

Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed

Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B